💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…
Profile for Neurocrine Biosciences, Inc. (NBIX)
« Back to company indexNBIX Chatter Timeline
Stock Ticker for NBIX
Most Active Tweeters for NBIX
| User | Tweets |
|---|---|
| @Tickeron | 5 |
| @MarcJacksonLA | 5 |
| @newsfilterio | 4 |
| @SweepCastApp | 4 |
| @FlashAlert_me | 4 |
Recent Tweets for NBIX
 |
@fintel_io Insider Matt Abernethy reports selling 1,645 shares of $NBIX for a total cost of $135,852.49 https://t.co/azHErUbBdv #FNTL December 3rd 2021, 10:12pm |
 |
@formwhisperscom #FWSells $NBIX ABERNETHY MATT, Chief Financial Officer of NEUROCRINE BIOSCIENCES INC sold 1,645 shares on 2021-12-0… https://t.co/BrB0oPxmxc December 3rd 2021, 10:12pm |
 |
@SwingTradeBot New 52 Week Low today: $NBIX $JUPW ... https://t.co/0EM4q8YtyQ December 2nd 2021, 8:12pm |
 |
@newsfilterio Form 3 (initial statement of beneficial ownership of securities) filed with the SEC $NBIX https://t.co/gHcqR1Ln2L December 2nd 2021, 8:12am |
|
@newsfilterio Onyia Jude (Chief Scientific Officer) acquired new securities, reported in a new form 4 filed with the SEC $NBIX https://t.co/13zslwYYUL December 2nd 2021, 8:12am |
 |
@Tickeron $NBIX's Aroon indicator drops into Downtrend on November 30, 2021. View odds for this and other indicators:… https://t.co/Ww315A8KtT December 2nd 2021, 5:12am |
 |
@quantisnow $NBIX ? SEC Form 4 filed by Onyia Jude https://t.co/hCIpdXl0E4 45 seconds delayed. December 2nd 2021, 1:12am |
 |
@FlashAlert_me $NBIX [15s. delayed] filed SEC form 4: Chief Scientific Officer Onyia Jude: Transacted Derivative Securities betwe… https://t.co/XcgoyhPI0T December 2nd 2021, 1:12am |
 |
@TWANewsOfficial $NBIX Officer ONYIA Updates Ownership of NEUROCRINE BIOSCIENCES INC (NBIX) December 2nd 2021, 1:12am |
|
@quantisnow $NBIX ? SEC Form 3 filed by new insider Onyia Jude https://t.co/5UH07H4a0P 45 seconds delayed. December 2nd 2021, 12:12am |
|
@FlashAlert_me $NBIX [15s. delayed] filed SEC form 3: Chief Scientific Officer Onyia Jude: https://t.co/f9eDjjRfmj December 2nd 2021, 12:12am |
|
@TWANewsOfficial $NBIX Officer ONYIA -Initial Statement of Ownership of NEUROCRINE BIOSCIENCES INC (NBIX) December 2nd 2021, 12:12am |
 |
@SweepCastApp SweepCast alerted: $NBIX with Unusual Options Activity Alerted on $90 CALL Expiring: 02-18-2022 worth 30K? |? Learn… https://t.co/BeoWAdOy5x December 1st 2021, 4:12am |
|
@newsfilterio Neurocrine Biosciences Appoints Jude Onyia, Ph.D., as Chief Scientific Officer $NBIX https://t.co/ve7v0Hmq3r December 1st 2021, 1:12am |
 |
@mehabecapital $NBIX @ 83.25 (-1.76%) : Neurocrine Biosciences picks former Eli Lilly executive as chief scientific officer https://t.co/JA54nemgeI November 30th 2021, 10:11pm |
 |
@MarcJacksonLA $NBIX Neurocrine Biosciences Appoints Jude Onyia, Ph.D., as Chief Scientific Officer https://t.co/oQPkROsSMk November 30th 2021, 9:11pm |
 |
@MarketCurrents $NBIX - Neurocrine Biosciences picks former Eli Lilly executive as chief scientific officer https://t.co/OJvt52uk33 November 30th 2021, 9:11pm |
|
@FlashAlert_me $NBIX [15s. delayed]: Issued Press Release on November 30, 16:05:00: Neurocrine Biosciences Appoints Jude Onyia, Ph… https://t.co/cchFgTe5ah November 30th 2021, 9:11pm |
 |
@phasefivebot $NBIX Neurocrine Biosciences Appoints Jude Onyia, Ph.D., as Chief Scientific Officer https://t.co/xaDahArxQL November 30th 2021, 9:11pm |
 |
@algobotnews Neurocrine names Jude Onyia, Ph.D., as Chief Scientific Officer $NBIX November 30th 2021, 9:11pm |
 |
@StockNewsBot2 $NBIX Neurocrine Biosciences Appoints Jude Onyia, Ph.D., as Chief Scientific Officer https://t.co/tfPheKV30d November 30th 2021, 9:11pm |
|
@quantisnow $NBIX ? Neurocrine Biosciences Appoints Jude Onyia, Ph.D., as Chief Scientific Officer https://t.co/Qo8RUk5OIL Th… https://t.co/aYME3FNdnM November 30th 2021, 9:11pm |
 |
@stock_titan $NBIX Neurocrine Biosciences Appoints Jude Onyia, Ph.D., as Chief Scientific Officer https://t.co/AjunXI408T November 30th 2021, 9:11pm |
 |
@YouCanFoolMost RT @Tickeron: $NBIX enters a Downtrend because Momentum Indicator dropped below the 0 level on November 2, 2021. View odds for this and oth… November 30th 2021, 7:11pm |
|
@Tickeron $NBIX enters a Downtrend because Momentum Indicator dropped below the 0 level on November 2, 2021. View odds for th… https://t.co/PJLY6MUV90 November 30th 2021, 7:11pm |
|
@Tickeron If you’re trading this week, Read This! $NBIX RSI Indicator left the oversold zone. #NeurocrineBiosciences… https://t.co/P8LZlfdBfX November 30th 2021, 4:11pm |
 |
@ShortAlgoTrades $NBIX Awaiting Short Signal. Stock Trading Ideas by https://t.co/jpmUt7T6MX #Investing #trading https://t.co/cHMz9jbrMK November 30th 2021, 12:11pm |
 |
@kwhenfinance Neurocrine Biosciences, Inc. Shares Near 52-Week Low - Market Mover https://t.co/jwQIsXmAiM $NBIX #stockmarket #kwhenfinance November 30th 2021, 9:11am |
|
@Tickeron $NBIX enters a Downtrend as Momentum Indicator dropped below the 0 level on November 2, 2021. View odds for this an… https://t.co/pjZJrI0bT3 November 30th 2021, 4:11am |
 |
@1anOnlyMary Neurocrine Biosciences Enters Oversold Territory ( $NBIX) https://t.co/pWpircBWw9 November 29th 2021, 7:11pm |
 |
@RamUltraAlgo Waiting for Short signal on $NBIX https://t.co/SRHwwHgn8E November 29th 2021, 6:11pm |
|
@MarcJacksonLA $NBIX Neurocrine Biosciences Enters Oversold Territory (NBIX) | NASDAQ https://t.co/Uqx3GZacTr November 29th 2021, 6:11pm |
 |
@LlcBillionaire Neurocrine Biosciences Enters Oversold Territory ( $NBIX) https://t.co/ik21JMtF1d November 29th 2021, 5:11pm |
 |
@humour_humourrr @lblegend33 $NBIX unfortunately is not cool for most biotech gamblers because they are cash flow positive and not <… https://t.co/F3CZMzfzMQ November 24th 2021, 5:11pm |
 |
@R5ive8 @ChimeraResearch Is $PFE buying $NBIX? November 24th 2021, 5:11pm |
 |
@lblegend33 Added $nbix 86s November 24th 2021, 3:11pm |
 |
@StckPro $NBIX NEW ARTICLE : Neurocrine Biosciences Gets Promising Drugs in Licensing Deal https://t.co/0V5jMuEzCS Get all t… https://t.co/nOFyDsTwB8 November 24th 2021, 3:11pm |
 |
@ShogunTrade $NBIX Awaiting buy signal. Trading simplified, free trial at https://t.co/6vnULU2sSf https://t.co/ThHVogn3De November 24th 2021, 12:11pm |
|
@RamUltraAlgo Waiting for Buy signal on $NBIX https://t.co/wETMv1UKMq November 23rd 2021, 6:11pm |
 |
@Jarvis_Alerts $NBIX 60P Exp:20-May-22 ? ? Total(Day): $50,830 #UnusualActivity Sign-up free for beta ver.:… https://t.co/lyttpIGiuY November 23rd 2021, 1:11pm |
|
@SweepCastApp SweepCast alerted: $NBIX with Unusual Options Activity Alerted on $60 PUT Expiring: 05-20-2022 worth 51K? |? See more in profile November 23rd 2021, 5:11am |
 |
@gnomikos1 RT @endpts: Eight months after Neurocrine $NBIX chronicled a flop for a mid-stage schizophrenia drug, the biotech is headed right back into… November 23rd 2021, 5:11am |
 |
@BioCentury A new home: #Sosei finds a new partner for muscarinic agonist programs in $NBIX with better terms than its 2016 dea… https://t.co/sVCpFk8SqF November 23rd 2021, 12:11am |
|
@Jarvis_Alerts $NBIX 60P Exp:20-May-22 ? ? Total(Day): $50,830 #UnusualActivity Sign-up free for beta ver.:… https://t.co/ex2M0YY1Ew November 22nd 2021, 10:11pm |
|
@MarcJacksonLA $NBIX Neurocrine stocks up on a biotech's psychiatric drugs https://t.co/H3zUCO5Z3A via @BioPharmaDive November 22nd 2021, 9:11pm |
|
@newsfilterio Neurocrine Pens $2.6B Pact With Sosei Heptares For Neuro Targets $NBIX https://t.co/mzqupoATUB November 22nd 2021, 5:11pm |
 |
@mttsubu RT @BentheFidler: Neurocrine stocks up on a biotech's psychiatric drugs https://t.co/crJtzCKI83 by @realJacobBell $NBIX November 22nd 2021, 4:11pm |
 |
@BentheFidler Neurocrine stocks up on a biotech's psychiatric drugs https://t.co/crJtzCKI83 by @realJacobBell $NBIX November 22nd 2021, 4:11pm |
 |
@endpts Eight months after Neurocrine $NBIX chronicled a flop for a mid-stage schizophrenia drug, the biotech is headed rig… https://t.co/ufEkLlTUSC November 22nd 2021, 3:11pm |
|
@MarcJacksonLA $NBIX Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonist… https://t.co/tDBoXyNHhz November 22nd 2021, 3:11pm |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2021. All rights reserved.
DrugPatentWatch Video Training
Decision-making for generic drug entry and branded drug lifecycle management
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
This course answers the following questions to help you adapt:
- ✓ When will key drug patents expire?
- ✓ How can I find, evaluate, and plan for generic market entry opportunities?
- ✓ How can I find proprietary out-of-court settlements and deal terms?